The scenario we outlined in our Q2 update has largely materialised, with Xspray reporting a Dasynoc CRL as the CDMO remains uncleared and the FDA requested additional batch data. This likely takes a 2026 launch off the table while elevating the dilution risk ahead of a potential approval.
LÄS MER
